These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8718566)

  • 21. Serum lipoprotein changes in dogs with renal disease.
    Behling-Kelly E
    J Vet Intern Med; 2014; 28(6):1692-8. PubMed ID: 25273603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome.
    Hu P; Lu L; Hu B; Du PF
    Scand J Clin Lab Invest; 2009; 69(6):680-6. PubMed ID: 19468931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholesterol metabolism in glomerular cells: effect of lipoproteins from nephrotic patients.
    Wanner C; Krämer-Guth A; Nauck M; Quaschning T; Pavenstädt H; Schollmeyer P
    Miner Electrolyte Metab; 1996; 22(1-3):39-46. PubMed ID: 8676822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dyslipidemia and renal disease: pathogenesis and clinical consequences.
    Wanner C; Quaschning T
    Curr Opin Nephrol Hypertens; 2001 Mar; 10(2):195-201. PubMed ID: 11224694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should hyperlipidemia in children with the nephrotic syndrome be treated?
    Querfeld U
    Pediatr Nephrol; 1999 Jan; 13(1):77-84. PubMed ID: 10100296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure.
    Kimak E; Ksiazek A; Solski J
    Clin Chem Lab Med; 2006; 44(1):64-9. PubMed ID: 16375588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pathophysiology and therapy of lipid metabolism disorders in kidney diseases].
    Olbricht CJ
    Klin Wochenschr; 1991 Aug; 69(11):455-62. PubMed ID: 1921228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipoprotein metabolism in renal replacement therapy: a review.
    Kronenberg F; Dieplinger H; König P; Utermann G
    Isr J Med Sci; 1996 Jun; 32(6):371-89. PubMed ID: 8682643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis.
    de Sain-van der Velden MG; Kaysen GA; Barrett HA; Stellaard F; Gadellaa MM; Voorbij HA; Reijngoud DJ; Rabelink TJ
    Kidney Int; 1998 Apr; 53(4):994-1001. PubMed ID: 9551409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
    Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid and lipoprotein metabolism in chronic kidney disease.
    Kaysen GA
    J Ren Nutr; 2009 Jan; 19(1):73-7. PubMed ID: 19121776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of decreasing renal function on lipoprotein profiles.
    Attman PO; Samuelsson O; Alaupovic P
    Nephrol Dial Transplant; 2011 Aug; 26(8):2572-5. PubMed ID: 21220758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Disturbances of lipoprotein metabolism in metabolic syndrome].
    Czyzewska M; Wolska A; Cwiklińska A; Kortas-Stempak B; Wróblewska M
    Postepy Hig Med Dosw (Online); 2010 Jan; 64():1-10. PubMed ID: 20093718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Hyperlipidemia Changes With Level of Kidney Function-Rationale.
    Ananthakrishnan S; Kaysen GA
    Adv Chronic Kidney Dis; 2016 Jul; 23(4):247-54. PubMed ID: 27324678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unusual dyslipoproteinemia in a patient with primary systemic amyloidosis and nephrotic syndrome. Role of excessive cholesterol synthesis.
    Eisenberg S; Oschry Y; Schattner A; Bentwich Z
    Isr J Med Sci; 1984 Mar; 20(3):224-31. PubMed ID: 6724868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on the effects of hemodialysis on plasma lipoproteins.
    Wada M; Minamisono T; Fujii H; Morita T; Akamatsu A
    Trans Am Soc Artif Intern Organs; 1975; 21():464-72. PubMed ID: 167493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased fasting plasma acylation-stimulating protein concentrations in nephrotic syndrome.
    Ozata M; Oktenli C; Gulec M; Ozgurtas T; Bulucu F; Caglar K; Bingol N; Vural A; Ozdemir IC
    J Clin Endocrinol Metab; 2002 Feb; 87(2):853-8. PubMed ID: 11836332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency.
    Lee DM; Knight-Gibson C; Samuelsson O; Attman PO; Wang CS; Alaupovic P
    Kidney Int; 2002 Jan; 61(1):209-18. PubMed ID: 11786103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.